A, Izu LT, Balke CW. Hypertensioninduced remodeling of cardiac excitation-contraction coupling in ventricular myocytes occurs prior to hypertrophy development. Am J Physiol Heart Circ Physiol 293: H3301-H3310, 2007. First published September 14, 2007; doi:10.1152/ajpheart.00259.2007.-Hypertension is a major risk factor for developing cardiac hypertrophy and heart failure. Previous studies show that hypertrophied and failing hearts display alterations in excitation-contraction (E-C) coupling. However, it is unclear whether remodeling of the E-C coupling system occurs before or after heart disease development. We hypothesized that hypertension might cause changes in the E-C coupling system that, in turn, induce hypertrophy. Here we tested this hypothesis by utilizing the progressive development of hypertensive heart disease in the spontaneously hypertensive rat (SHR) to identify a window period when SHR had just developed hypertension but had not yet developed hypertrophy. We found the following major changes in cardiac E-C coupling during this window period. 1) Using echocardiography and hemodynamics measurements, we found a decrease of left ventricular ejection fraction and cardiac output after the onset of hypertension. 2) Studies in isolated ventricular myocytes showed that myocardial contraction was also enhanced at the same time.
heart failure; action potential; L-type Ca 2ϩ channel; ryanodine receptor SYSTEMIC HYPERTENSION is a major risk factor for cardiac hypertrophy and heart failure. The severe impact of hypertensive heart disease (HHD) is underscored by the fact that ϳ30% of the US adult population have hypertension (17) and 60% of these develop cardiac hypertrophy (13, 36) . However, the cellular and molecular mechanisms linking hypertension to heart diseases remain unclear. Extensive evidence has demonstrated that cardiac hypertrophy is associated with remodeling of the excitation-contraction (E-C) coupling system and enhanced myocardial contraction (11, 22, 33) , and heart failure is marked by diminished contractility (2, 3, 6, 18 ). An important yet unanswered question is whether changes in E-C coupling are directly linked to hypertension or are merely markers of later-stage hypertrophy. We hypothesized that hypertension might directly cause remodeling of the cardiac E-C coupling system.
Previous studies using hearts that had already developed significant hypertrophy or heart failure were confounded by difficulties in separating the causal mechanism of disease from markers of advanced pathological conditions. To test our hypothesis, here we exploited the progressive development of HHD through distinct disease stages in the spontaneously hypertensive rat (SHR) (12, 32) . With the SHR model, we identified a "window" period when the animals had just developed hypertension but before the development of cardiac hypertrophy. Our studies reveal a direct link between hypertension and profound changes in cardiac E-C coupling at both the whole heart and cellular levels. An interesting new finding is that the systolic function in vivo was depressed by hypertension before the development of "compensated hypertrophy," while at the same time, myocardial contraction was enhanced. Importantly, we found that the enhancement of myocardial contraction is caused by concerted changes in cellular E-C coupling, suggesting an immediate link between the onset of hypertension and an upregulation of the Ca 2ϩ signaling that is expected to induce hypertrophy and heart failure on prolonged exposure to systemic hypertension.
MATERIALS AND METHODS
Animals and blood pressure measurement. Male SHR and normotensive Wistar-Kyoto rats (WKY) were purchased from Harlan (Indianapolis, IN) at the age of 4 -5 wk. Blood pressure (BP) was monitored weekly in nonanesthetized rats with the standard noninvasive tail cuff method (IITC, model 29-SSP). Animal handling and all procedures were performed strictly in accordance with National Institutes of Health (NIH) guidelines and the Institutional Animal Care and Use Committee protocols approved by the University of Kentucky and by the University of Maryland.
Echocardiographic measures of cardiac function. The animals were anesthetized with 1.5% isoflurane supplemented with O 2. Echocardiography was performed with a SonoHeart Elite echocardiograph (SonoSite, Bothell, WA) equipped with a C11/7-4 11-mm broadband curved array transducer. Two-dimensional guided M-mode images of the left ventricle (LV) were taken with the parasternal short-axis view at the level of the papillary muscles. M-mode measurements included LV anterior-posterior cavitary dimension at end systole (LVDs) and end diastole (LVDd . Rectal temperature was monitored and maintained at 37.5-38°C. A 3-Fr Mikrotipped pressure transducer (SPR-249A, Millar Instruments, Houston, TX) was inserted into the aortic arch for measurement of BP and then advanced into the LV for measurement of LV pressure. A 1.4-F Mikro-tipped pressure transducer (SPR-671, Millar Instruments) was inserted into the vena cava for measurement of central venous pressure. Data were collected with the MP100 system (BioPac Systems, Goleta, CA). After a 30-min stabilization period, both transducers were removed and replaced with a thermistor-tipped catheter (3F, Edwards Lifesciences, Irvine, CA) into the aorta and a PE-25 catheter into the right atrium. Cardiac output was measured in triplicate with a cardiac output computer (Vigilance, Edward Lifesciences), by injecting 0.3 ml of iced saline into the right atrium and sampling the temperature from the aorta.
Cell isolation. The rats were anesthetized with Nembutal (100 mg/kg ip). After testing for the suppression of reflexes, the hearts were explanted via midline thoracotomy. A standard enzymatic technique was used to isolate the ventricle myocytes. Briefly, the heart was mounted on a Langendorff system and perfused with a modified Tyrode solution containing (in mmol/l) 135 NaCl, 4 KCl, 1.0 MgSO 4, 0.34 NaH2PO4, 15 glucose, 10 HEPES, and 10 taurine, pH 7.25 (adjusted with NaOH), for ϳ4 min; the perfusion solution was prewarmed to 37°C and bubbled with 100% O 2. Collagenase B (ϳ1 mg/ml, F. Hoffmann-La Roche), protease type XIV (ϳ0.1 mg/ml), . C: average diastolic BP in WKY(4 -6 wk) (n ϭ 52) and SHR(4 -6 wk) (n ϭ 56) and in WKY (8 -12 wk) and SHR (8 -12 wk) . Cardiac hypertrophy was measured in (from left to right) WKY(4 -6 wk), SHR(4 -6 wk), WKY (8 -12 wk) , and SHR(8 -12 wk) with 2 indexes: the wet heart weight-to-body weight ratio (HW/BW, from left to right n ϭ 5, 7, 11, and 11 animals; D) and the whole cell membrane capacitance of ventricular myocytes (Cm, from left to right n ϭ 18, 16, 13, and 12 cells; E). As the animals grew older, HW/BW decreased owing to a larger increase in BW than HW, while Cm of cells increased in correspondence to growth of the cell size. However, there was no significant difference between SHR and age-matched WKY in either HW/BW or Cm, demonstrating an absence of cardiac hypertrophy at the tissue and cell levels. n.s., Not significant. 0.1% BSA, and 20 M Ca 2ϩ were then added into the perfusion solution, and the heart was digested for ϳ15 min. The ventricular tissue was cut down and minced with tissue scissors; the remaining tissue was further incubated in the enzyme solution at 37°C and minced again to collect isolated ventricular myocytes. The cells were stored in Tyrode solution containing 1 mM Ca 2ϩ at room temperature and used within 10 h after isolation.
Chemicals and reagents were purchased from Sigma-Aldrich unless otherwise specified.
Ventricular myocyte contraction measurement. Load-free contraction of isolated ventricular myocytes was measured with the IonOptix system (IonOptix), which records the sarcomere pattern to calculate the changes in the sarcomere spacing with a fast Fourier transform algorithm. The cells were field stimulated (voltage pulse of 4 ms and 5-20 V across the chamber) at 1-Hz frequency and room temperature (22-23°C) .
Sharp electrode measurement of action potentials. Action potential was measured from LV tissue with the sharp electrode technique. The tissue was continuously superfused in the bath solution containing (in mmol/l) 120 NaCl, 4 KCl, 1 MgCl 2, 1 CaCl2, 25 NaHCO3, 10 HEPES, and 10 glucose, pH 7.3 (adjusted with NaOH). The tissue was paced at 500-ms cycle length with 3-ms biphasic stimuli delivered through a bipolar platinum-iridium electrode. After at least 1-h preconditioning at room temperature to reach steady state, the recordings were made with glass microelectrodes filled with 3 M KCl. Data were analog filtered at 20 KHz and sampled at a rate of 10 [Ca 2ϩ ]i. The holding potential was set to Ϫ80 mV. First, a depolarizing step to Ϫ40 mV of 800-ms duration was used to inactivate Na ϩ channels. Second, a test pulse of 200-ms duration was used to record the current-voltage (I-V) relationship of I Ca(L). Third, the cell was repolarized to the holding potential. The interval between pulses was set to 5 s to allow sufficient time for the Ca 2ϩ transient to return to the resting level. No preconditioning was used for I-V measurement. For sarcoplasmic reticulum (SR) load measurement, the cell was preconditioned by repetitive depolarizing pulse from Ϫ80 mV to 0 mV to reach steady state before the caffeine depletion experiment. Series resistance compensation and supercharging were used to reduce the voltage offset and to speed up the capacitive transient. Currents were filtered at 2 kHz with an analog 4-pole Bessel filter and digitized at 5 kHz. To record I Ca(L), we used (Rmax) were obtained by a previously described method (34) . The time course of the fluorescence ratio [R(t)] was best fitted to the function
where H(t) ϭ 1 for t Ն 0, H(t) ϭ 0 for t Ͻ 0, a i (i ϭ 1...5) are descriptional parameters that are used to fit R curve to exponential functions, and F b denotes background fluorescence. [Ca 2ϩ ]i was calculated by substituting R from Eq. 1 into the following equation (20) 
where ␤ is an instrument-dependent scaling factor, which can be obtained from fitting the calibration curve. 
RESULTS

Onset of hypertension in SHR.
To study the effect of hypertension without the confounding effects of cardiac hypertrophy, we identified a period at early phase of HHD when SHR had just developed hypertension but had not yet developed hypertrophy. BP measurements (Fig. 1A) showed that SHR were prehypertensive during their first 4 -6 wk of life (systolic BP Ͻ 130 mmHg) and then rapidly developed hypertension between 8 and 12 wk of age. The average values of systolic (Fig. 1B) and diastolic (Fig. 1C ) BP in 4-to 6-wk-old prehypertensive SHR were 124 Ϯ 26 and 102 Ϯ 27 mmHg (n ϭ 36), respectively, similar to those in age-matched WKY (systolic BP 119 Ϯ 11 mmHg and diastolic BP 99 Ϯ 13, n ϭ 21; t-test, P ϭ 0.6 and 0.5). During the onset of hypertension between 8 and 12 wk of age, SHR developed high systolic and diastolic BP of 176 Ϯ 22 and 126 Ϯ 37 mmHg (n ϭ 52), respectively, significantly higher than those in age-matched WKY (systolic BP 135 Ϯ 17 mmHg and diastolic BP 97 Ϯ 25, n ϭ 56; t-test, P ϭ 8.1eϪ27 and 4.8eϪ06). After the onset of systolic and diastolic hypertension, SHR maintained essential hypertension throughout the development of cardiac hypertrophy and heart failure in 1.5-2 yr of life span (9) .
Changes in cardiac performance at onset of hypertension. To study the changes in cardiac function at the onset of hypertension, echocardiography was performed in the SHR at 8 and 12 wk of age, which mark the start and the end of the window period for the onset of hypertension. As shown in Table 1 , there was no significant difference in echocardiographic parameters between SHR and WKY at 8 wk of age. However, at 12 wk of age SHR displayed ϳ10% decrease in LV FS and 4.4% decrease in LV ejection fraction, demonstrating the effects of increased workload under hypertension. SHR also had larger LVDd and LV posterior wall thickness, which could be attributed to 1) a faster growth of SHR than WKY (body wt 297.7 Ϯ 22.1 vs. 281.7 Ϯ 19.1 mg; t-test, P Ͻ 0.05) and 2) possible hypertrophy or hyperplasia. The question of hypertrophy is addressed in Window period at onset of hypertension before cardiac hypertrophy development below.
We further examined hemodynamics in 12-wk-old hypertensive SHR compared with age-matched normotensive WKY, using catheter-based methods. As shown in Table 2 , SHR displayed markedly elevated systolic and diastolic BP, and systemic vascular resistance was significantly increased by ϳ100%. Cardiac output and stroke volume were reduced by ϳ25%. Although the rate of change of pressure with time (dP/dt) was increased in SHR, after normalizing to the P value, the average (dP/dt)/P values were 31 s Ϫ1 in SHR and 41 s Ϫ1 in WKY, indicating a decreased cardiac function consistent with decreased cardiac output and stroke volume. Thus the onset of hypertension is associated with a moderate depression in the cardiac pump function due to increased systemic vascular resistance.
Window period at onset of hypertension before cardiac hypertrophy development. We examined cardiac hypertrophy with two indexes, 1) the wet heart weight-to-body weight ratio (HW/BW), which measures hypertrophy and hyperplasia at the tissue level, and 2) the whole cell membrane capacitance in isolated ventricular myocytes, which most accurately measures hypertrophy at the cellular level (15) . Figure 1 , D and E, show that at 4 -6 wk of age SHR and WKY had similar HW/BW (7.9 Ϯ 1.1 mg/g in SHR vs. 7.2 Ϯ 0.6 mg/g in WKY; t-test, P ϭ 0.16) and similar whole cell membrane capacitance (82.2 Ϯ 24.8 pF in SHR vs. 82.2 Ϯ 18.4 pF in WKY; P ϭ 1.0). In both SHR and WKY, as the animals grew older, HW/BW decreased, owing to a larger gain in BW than in HW, and cell membrane capacitance increased because of normal growth of the cell size. Nevertheless, compared with age-matched WKY, 8-to 12-wk-old SHR continued to display similar values in HW/BW (5.3 Ϯ 1.0 mg/g in SHR vs. 5.2 Ϯ 0.5 mg/g in WKY; P ϭ 0.83) and in cell membrane capacitance (153.6 Ϯ 43.8 pF in SHR vs. 156.2 Ϯ 31.8 pF in WKY; P ϭ 0.87), demonstrating a lack of discernible hypertrophy at the tissue and cell levels.
These data establish two distinct stages in HHD development in SHR: at 4 -6 wk of age SHR are prehypertensive, and at 8 -12 wk of age SHR become hypertensive but have not yet developed hypertrophy. Subsequent to this period, cardiac hypertrophy was found to develop progressively in SHR between 3 and 18 mo of age, and heart failure typically occurs between 18 and 24 mo of age as reported in previous publications from our group (9, 33) and others (14, 16) .
Enhanced myocardial contractility at onset of hypertension. To study changes in cellular E-C coupling, we used isolated ventricular myocytes, which are removed from changes in BP or neuronal and hormonal influences in vivo. Figure 2 shows the measurements of the load-free cell contraction under field stimulation. Compared with age-matched WKY, the cells from 12-wk-old hypertensive SHR displayed significant increases in fractional shortening (14.3 Ϯ 3.6% in SHR vs. 9.1 Ϯ 3.4% in WKY; P ϭ 0.02), velocity of shortening (Ϫ3.9 Ϯ 1.6 vs. Ϫ1.9 Ϯ 0.8 m/s per sarcomere; P ϭ 0.02), and velocity of relaxation (2.8 Ϯ 1.2 vs. 1.0 Ϯ 0.7 m/s per sarcomere; P ϭ 0.01). The diastolic sarcomere length was largely the same in the cells from SHR and WKY (1.82 Ϯ 0.05 m vs. 1.80 Ϯ 0.02 m; P ϭ 0.5), indicating unchanged diastolic Ca 2ϩ concentration. In comparison, 6-wk-old prehypertensive SHR had fractional shortening similar to that of age-matched WKY (9.4 Ϯ 4.5% vs. 10.9 Ϯ 4.3%, n ϭ 12; P ϭ 0.5).
Prolonged action potentials at onset of hypertension. Enhanced myocardial contraction could be influenced by two major factors: the action potential and the E-C coupling gain. We measured action potentials in LV tissue of 12-wk old SHR and WKY. Figure 3 shows that action potentials had significantly longer durations in SHR than in WKY. The action potential duration from the peak to 50% decay (APD 50 ), for example, was 39.8 Ϯ 18.9 ms in SHR (n ϭ 4 animals) versus 10.0 Ϯ 2.7 ms in WKY (n ϭ 3 animals; t-test, P ϭ 0.03).
Prolonged action potential should allow more Ca 2ϩ entry through L-type Ca 2ϩ channels during excitation, boosting the trigger signal for E-C coupling.
I Ca(L) under voltage-clamp conditions. E-C coupling in ventricular myocytes was studied by simultaneously measuring [Ca 2ϩ ] i and I Ca(L) under whole cell voltage-clamp conditions. To investigate hypertension-related changes in cardiac E-C coupling, we used SHR at two distinctive stages: prehypertensive SHR between 4 and 6 wk of age [SHR(4 -6 wk)] and hypertensive SHR between 8 and 12 wk of age [SHR (8 -12 wk)]. Age-matched WKY groups [WKY(4 -6 wk) and WKY(8 -12 wk)] were used to separate age-related changes from disease-related changes.
We first examine I Ca(L) under voltage-clamp conditions. Figure 4 , A and B, show representative I Ca(L) recordings from A: sample traces of action potentials from 12-wk-old WKY and SHR. B: action potential durations (APDs) were measured from the peak to 25% (APD25), 50% (APD50), 75% (APD75), and 90% (APD90) decay, which demonstrate significantly longer APD in SHR (n ϭ 4 animals) than in WKY (n ϭ 3 animals; *P Ͻ 0.05, t-test) at APD50, APD75, and APD90.
WKY and SHR at prehypertensive (4 -6 wk) and hypertensive (8 -12 wk) stages. Figure 4 , C and D, show the peak I-V relationship; there was no significant difference in all cell groups across the entire voltage range. For example, the peak I Ca(L) at 5 mV was Ϫ4.28 Ϯ 1.72, Ϫ4.89 Ϯ 1.39, Ϫ4.25 Ϯ 1.95, and Ϫ4.70 Ϯ 0.72 pA/pF for WKY(4 -6 wk), SHR(4 -6 wk), WKY(8 -12 wk), and SHR(8 -12 wk), respectively. The inactivation rate of I Ca(L) () was largely the same between SHR(4 -6 wk) and WKY(4 -6 wk) (Fig. 4E) . However, SHR(8 -12 wk) displayed a slightly slower than WKY (8 -12 wk) in the voltage range between 20 and 35 mV (P Ͻ 0.05) (Fig. 4F) . There was no age-related change between WKY(4 -6 wk) and WKY(8 -12 wk) in either peak current density or .
[ Figure 5E shows that SHR(4 -6 wk) had J rel similar to WKY(4 -6 wk) across the entire voltage range. Importantly, SHR(8 -12 wk) showed larger J rel than WKY(8 -12 wk) (Fig. 5F) .
Increased E-C coupling gain at onset of hypertension. Knowing the trigger signal and the SR Ca 2ϩ release flux, we can now calculate the E-C coupling gain by taking the ratio between J rel and peak I Ca(L) , gain ϭ J rel /peak I Ca(L) . Figure 6 shows the E-C coupling gain in relationship to transmembrane voltage. While SHR(4 -6 wk) had gain similar to WKY(4 -6 wk) across the entire voltage range, SHR(8 -12 wk) had significantly larger gain than WKY(8 -12 wk) (2-way ANOVA test, P Ͻ 0.0001 for difference between strains). Therefore, at the onset of hypertension, SHR displayed higher E-C coupling Fig. 4 . The voltage (V)-clamp protocol consists of the following steps: the holding potential was set to Ϫ80 mV; the membrane potential was first depolarized to Ϫ40 mV for a duration of 900 ms to inactivate Na ϩ channels; step pulses of 5-mV increments were then used to depolarize the membrane potential from Ϫ35 mV to ϩ60 mV to measure L-type Ca 2ϩ current [ICa(L)]. Sample traces of ICa(L) during the depolarization pulse to ϩ5 mV are shown (A and B) . The peak current-voltage (I-V) relationship showed no significant difference between the strains in SHR(4 -6 wk) vs. WKY(4 -6 wk) (C) or in SHR (8 -12) vs. WKY(8 -12) (D). The inactivation rate of ICa(L) () was calculated by fitting the declining phase of ICa(L) to a single exponential function. There was no significant difference in the inactivation rate between SHR(4 -6 wk) and WKY(4 -6 wk) (t-test, P Ͼ 0.05; E). SHR(8 -12 wk) displayed slower than WKY (8 -12 wk) gain. This increased gain might be caused by changes in the SR Ca 2ϩ load or in the ryanodine receptor (RyR) activity. Maintained SR Ca 2ϩ load. As a key determinant of the E-C coupling gain, the SR Ca 2ϩ load was examined by using caffeine (20 mM) to rapidly deplete the SR Ca 2ϩ stores, while simultaneously measuring the [Ca 2ϩ ] i transient and the Na ϩ / Ca 2ϩ exchange current (I NCX ) (Fig. 7) . The total amount of SR Ca 2ϩ release during the caffeine application (20 s) was calculated from the integral of I NCX using a 3 Na ϩ /1 Ca 2ϩ stoichiometry. Thus calculated, the total amount of SR Ca 2ϩ load normalized to cell membrane capacitance for WKY(4 -6 wk), SHR(4 -6 wk), WKY(8 -12 wk), and SHR(8 -12 wk) was 
DISCUSSION
We hypothesized that the onset of hypertension might cause immediate remodeling of the Ca 2ϩ signaling system that alters whole heart function and induces cardiac hypertrophy. To test this hypothesis, we identified a window period in SHR when the animals had just developed hypertension but not yet developed hypertrophy. Thus changes in SHR observed during this period precede hypertrophy and can be attributed to the effects of hypertension.
First, we found that both systolic and diastolic BP increased rapidly in SHR between 8 and 12 wk of age (Fig. 1) . During the same period the SHR heart had not yet developed detectable hypertrophy, although hypertrophy would later develop progressively in SHR between 3 and 18 mo of age (9, 14, 16, 33) . Second, we found that the onset of hypertension in 12-wk-old SHR is associated with a decrease in cardiac output and stroke volume, demonstrating a depression of cardiac function under increased systemic vascular resistance (Table 2 ). This depression of cardiac function demonstrates an interesting contrast to the restored cardiac function after development of "compensated hypertrophy" at a later stage of HHD (4, 33) . Third, dP/dt was increased in 12-wk-old SHR hearts, which could be explained by increased myocardial contractility or simply by increased P values. After normalization, (dP/dt)/P values show an average of 31 s Ϫ1 in SHR and 41 s Ϫ1 in WKY, again indicating depressed cardiac function. To further investigate possible changes in myocardial contraction, we used isolated ventricular myocytes, which allowed us to examine the changes at the cellular level separated from the BP change or neuronal/hormonal influences that affect whole heart function.
One major finding is that the ventricular myocyte from 12-wk-old SHR has enhanced contraction under field stimulation (Fig. 2) . To investigate the cause for enhanced cell contraction, we examined the following important determinants of E-C coupling and found changes in SHR at the onset of hypertension compared with prehypertensive SHR or agematched WKY controls. First, action potential measurements in LV tissue showed that SHR had markedly prolonged APD (Fig. 3) , which should increase the Ca 2ϩ entry through L-type Ca 2ϩ channels during excitation and therefore increase the trigger signal for E-C coupling. Second, under voltage-clamp conditions I Ca(L) density was unchanged in SHR (Fig. 4) , indicating unchanged L-type Ca 2ϩ channel function although prolonged action potential should cause more Ca 2ϩ entry during excitation. Third, under the voltage-clamp condition with unchanged trigger signal, the Ca 2ϩ -induced Ca 2ϩ release from the SR was significantly increased in SHR (Fig. 5) , which translates to increased E-C coupling gain (Fig. 6) . Prolonged action potential and increased E-C coupling gain should act synergistically to increase the Ca 2ϩ transient during excitation and cause enhanced myocardial contraction (Fig. 2) .
In a longitudinal view along the development of HHD, this study shows that the prehypertensive SHR (4 -6 wk old) has E-C coupling parameters similar to those of age-matched WKY; however, the onset of hypertension in SHR (8 -12 wk old) is associated with immediate remodeling of the E-C coupling characterized by 1) augmented Ca 2ϩ transient, 2) unchanged resting level Ca 2ϩ , 3) unchanged I Ca(L) density, and 4) unchanged SR Ca 2ϩ load. These Ca 2ϩ signaling characteristics are similar to those previously observed in 6-mo-old SHR after development of overt hypertrophy. (33) With more advanced hypertrophy at 10 -11 mo of age, SHR hearts displayed not only increased systolic performance indicative of augmented systolic Ca 2ϩ transient, but also delayed relaxation and increased diastolic stiffness suggesting altered diastolic Ca 2ϩ handling (10, 16) . Indeed, delayed relaxation of Ca 2ϩ transient and elevated resting Ca 2ϩ concentration was found in 20-to 24-mo old SHR at late-stage hypertrophy and heart failure (37) . Together, the above data show that remodeling of the E-C coupling system develops gradually as HHD progresses through distinctive stages from hypertension to hypertrophy and then to heart failure. Our data establish that the augmented Ca 2ϩ transient is not merely associated with hypertrophied hearts, but, in fact, precedes hypertrophy and possibly plays a role in inducing hypertrophy.
Functional changes in Ca 2ϩ signaling pathways point to possible changes in the expression and modulation of Ca 2ϩ -handling molecules. The present study show that in 8-to 12-wk-old SHR, I Ca(L) density was unchanged compared with age-matched WKY or 4-to 6-wk-old SHR, indicating maintained L-type Ca 2ϩ channel expression. Maintained I Ca(L) was also observed at later stages of hypertrophy in SHR [i.e., 16-wk (7), 6-mo (33), 3-mo and 18-mo (8)-old SHR] and in many other hypertrophy models in rodents and humans (30) . With the trigger signal, I Ca(L) maintained, augmentation of the SR Ca 2ϩ release could result from several possible causes: increased SR Ca 2ϩ load, increased RyR2 expression level, or increased RyR2 activity by modulation. In 8-to 12-wk-old SHR, the SR load was found unchanged (Fig. 7) ; the RyR2 protein expression level is unlikely to change since the RyR2 protein expression level is identical in 6-mo-old SHR and WKY (33) . Hence, it is most likely that augmented SR Ca 2ϩ release in 8-to 12-wk-old SHR is caused by modulation of RyR2 activity at the onset of hypertension.
It has been proposed that RyR2 activity can be modulated by protein kinase A phosphorylation at the serine 2808 site (26, 27) or by Ca 2ϩ /calmodulin-dependent kinase II (CaMKII) phosphorylation at the serine 2814 site (1, 38) . We detected no change of RyR2 serine 2808 phosphorylation in SHR during early stages of hypertension and hypertrophy until late-stage heart failure (Ͼ1.5 yr old) (9) . Since CaMKII activity was found to be elevated in 12-to 13-wk-old SHR (5), it is likely that CaMKII phosphorylation of RyR2 serine 2814 may cause increased RyR2 activity at the onset of hypertension.
In summary, the present study is the first to demonstrate in a progressive HHD model that profound changes in Ca 2ϩ signaling already occur at the onset of hypertension and precede hypertrophy development. Functionally, hypertensioninduced augmentation of Ca 2ϩ transient causes an acute enhancement of myocardial contraction that serves to compensate, at least partially, for the increased workload to maintain the cardiac output. However, increased Ca 2ϩ signaling strength should also cascade through the calmodulin, calcineurin, and CaMKII signaling pathways that are known to induce gene transcription and hypertrophic cell growth (19, 21, 28, 31, 39 -41) . Therefore, upregulated Ca 2ϩ signaling is expected to induce cardiac hypertrophy under prolonged exposure to systemic hypertension. This immediate link between essential hypertension and upregulation of Ca 2ϩ signaling provides new insights into possible therapeutic strategies for early prevention of HHD.
